VIRALGEN VECTOR CORE SL

VIRALGEN VECTOR CORE SL specializes in the manufacturing of pharmaceutical preparations, with a focused technical expertise in viral vector production and gene therapy platforms. The company leverages advanced bioprocessing techniques to develop and scale viral vectors used in therapeutic and vaccine applications, demonstrating proficiency in cell culture systems, downstream purification, and quality control protocols aligned with cGMP standards. Their work supports the development of novel biologics, particularly in the realm of gene delivery systems, where precision in vector characterization and batch consistency is critical. Differentiators include specialized know-how in adenoviral and AAV vector manufacturing, as well as process optimization for clinical-grade production under regulated environments. The contractor has delivered services to the Department of Health and Human Services, indicating direct engagement in federal health innovation initiatives. Their work likely supports HHS programs focused on advanced therapeutics, including those under NIH or CDC oversight, where viral vector platforms are essential for next-generation vaccines and gene-based interventions. The relationship suggests alignment with public health priorities requiring scalable, compliant manufacturing of biological products. The primary NAICS code 325412 reflects a dedicated focus on pharmaceutical preparation manufacturing, specifically the production of active biologic ingredients and finished dosage forms derived from biological sources. This positions VIRALGEN VECTOR CORE SL within the advanced biopharmaceutical sector, serving markets requiring high-complexity, low-volume, high-purity outputs—such as oncology, rare disease, and infectious disease therapeutics. As an entity structured under code X6 and based in Donostia-San Sebastián, Spain, the company operates as a specialized European biomanufacturer with direct access to U.S. federal procurement channels. While no government certifications are listed, their ability to secure a HHS contract implies adherence to stringent regulatory frameworks required for U.S. government biological product supply. Their geographic presence enables cross-border collaboration in global health initiatives while maintaining compliance with both EU and U.S. regulatory expectations.